Cutaneous T-Cell Lymphoma clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

    open to eligible people ages 18 years and up

    This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.

    at UCLA

  • Registry for People With T-cell Lymphoma

    Sorry, not currently recruiting here

    The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

    at UCSD UCSF

Our lead scientists for Cutaneous T-Cell Lymphoma research studies include .

Last updated: